Carobeli Lucimara R, Meirelles Lyvia E de F, Damke Gabrielle M Z F, Damke Edilson, Souza Maria V F de, Mari Natália L, Mashiba Kayane H, Shinobu-Mesquita Cristiane S, Souza Raquel P, Silva Vânia R S da, Gonçalves Renato S, Caetano Wilker, Consolaro Márcia E L
Department of Clinical Analysis and Biomedicine, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil.
Department of Chemistry, Universidade Estadual de Maringá, Maringá 87020-900, PR, Brazil.
Pharmaceutics. 2021 Dec 2;13(12):2057. doi: 10.3390/pharmaceutics13122057.
Cervical cancer is one of the most common causes of cancer-related deaths in women worldwide. Despite advances in current therapies, women with advanced or recurrent disease present poor prognosis. Photodynamic therapy (PDT) has emerged as an effective therapeutic alternative to treat oncological diseases such as cervical cancer. Phthalocyanines (Pcs) are considered good photosensitizers (PS) for PDT, although most of them present high levels of aggregation and are lipophilic. Despite many investigations and encouraging results, Pcs have not been approved as PS for PDT of invasive cervical cancer yet. This review presents an overview on the pathophysiology of cervical cancer and summarizes the most recent developments on the physicochemical properties of Pcs and biological results obtained both in vitro in tumor-bearing mice and in clinical tests reported in the last five years. Current evidence indicates that Pcs have potential as pharmaceutical agents for anti-cervical cancer therapy. The authors firmly believe that Pc-based formulations could emerge as a privileged scaffold for the establishment of lead compounds for PDT against different types of cervical cancer.
宫颈癌是全球女性癌症相关死亡的最常见原因之一。尽管当前治疗方法有所进步,但患有晚期或复发性疾病的女性预后较差。光动力疗法(PDT)已成为治疗宫颈癌等肿瘤疾病的一种有效治疗选择。酞菁(Pcs)被认为是用于PDT的良好光敏剂(PS),尽管它们中的大多数呈现出高水平的聚集且具有亲脂性。尽管进行了许多研究并取得了令人鼓舞的结果,但Pcs尚未被批准作为浸润性宫颈癌PDT的PS。本综述概述了宫颈癌的病理生理学,并总结了Pcs物理化学性质的最新进展以及在荷瘤小鼠体外实验和过去五年报道的临床试验中获得的生物学结果。目前的证据表明,Pcs有作为抗宫颈癌治疗药物的潜力。作者坚信,基于Pc的制剂可能成为建立针对不同类型宫颈癌的PDT先导化合物的优先支架。